An Ounce of Prevention

Series Program Overview

Hemophilia A and B are rare inherited bleeding disorders caused by a deficiency in factor VIII (FVIII) or factor IX (FIX), respectively, leading to spontaneous and posttraumatic bleeding. Acute bleeding episodes cause pain and debilitation, while long-term consequences include joint damage, infections, chronic pain, anxiety, depression, and financial and social burdens, all of which contribute to disability and poor quality of life (QoL). Traditional management relies on intravenous (IV) factor replacement or bypass agent therapy, but these approaches have significant limitations, including treatment burden, development of inhibitors that reduce efficacy, and high annualized bleeding rates (ABRs) despite prophylactic therapy. Fortunately, nonfactor therapies are available that can overcome some of these limitations and improve patient outcomes. In this Hematology News: Hemophilia Edition program, An Ounce of Prevention: Exploring Nonfactor Therapies in Hemophilia, expert hematology faculty provide evidence-based insights, real-world clinical perspectives, and expert guidance to help clinicians effectively integrate nonfactor therapies into their practices.